Key Highlights:
- Zydus Lifesciences has partnered with Torrent Pharmaceuticals to co-market semaglutide injection (15 mg/3 ml) in India, bringing together Zydus’ manufacturing strength and Torrent’s wide market reach to improve access to GLP-1 therapies.
- Under the deal, Zydus will manufacture and supply the drug, while Torrent gets semi-exclusive rights to sell it as Sembolic; Zydus will continue with Semaglyn, Mashema, and Alterme, with an upfront licensing fee part of the agreement.
- What makes this offering stand out is its prefilled cartridge with a reusable pen device, designed to make dosing simpler and improve adherence, especially important for patients managing type 2 diabetes and weight loss over the long term.
Implications:
The partnership lets Zydus scale its semaglutide franchise while tapping Torrent’s strong chronic-care reach, accelerating GLP‑1 penetration without stretching its own front‑end bandwidth.
Torrent gains a high‑profile metabolic asset without development risk, and the reusable pen format helps both companies compete on convenience and adherence rather than only on price.
Source: Express Pharma
Other Articles
Next
Previous
No Comment! Be the first one.